This trial will compare a new once-weekly combination insulin to daily insulin in people with type 2 diabetes, to see how well it controls blood sugar levels.
- Type 2 Diabetes
1 Primary · 10 Secondary · Reporting Duration: From week 50 (V52) to week 52 (V54)
Awards & Highlights
2 Treatment Groups
Insuling glargine/insulin aspart
1 of 2
1 of 2
680 Total Participants · 2 Treatment Groups
Primary Treatment: IcoSema · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
How old are they?
|18 - 65||62.5%|
What site did they apply to?
|Novo Nordisk Investigational Site||50.0%|
What portion of applicants met pre-screening criteria?
|Did not meet criteria||35.7%|
How many prior treatments have patients received?
Why did patients apply to this trial?
- "Saw an ad on Facebook"
What questions have other patients asked about this trial?
- "How long does this investigation last?"
How responsive is this trial?
Average response time
- < 2 Days
Typically responds via
Most responsive sites:
- Novo Nordisk Investigational Site: < 48 hours
- 2021. "A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05013229.
Frequently Asked Questions
How many human subjects are included in this experiment?
"Correct, the clinical trial is still recruiting patients. 39 sites across the nation are looking for a total of 680 participants. The study was originally posted on 11/30/2021 and last updated on 11/7/2022 according to clinicaltrials.gov" - Anonymous Online Contributor
For what conditions is IcoSema regularly prescribed?
"IcoSema can be used to manage hyperglycemia, type 2 diabetes mellitus, and help patients get active through exercise." - Anonymous Online Contributor
Is IcoSema likely to lead to any adverse health effects?
"IcoSema's safety is estimated to be a 3. This rating comes from the fact that it is a Phase 3 trial, which suggests that not only does some data support efficacy, but multiple rounds of data support safety." - Anonymous Online Contributor
Are the results of IcoSema backed by other scientific research?
"Currently, there are 29 different clinical trials evaluating the efficacy of IcoSema. Of these active studies, 7 have progressed to Phase 3 testing. The majority of these trials taking place in Baltimore, MD; however, 477 locations across the world are running similar investigations." - Anonymous Online Contributor